The Precise MRD™ Test from Myriad Oncology™ is a tumor-informed assay that is whole genome sequencing (WGS)-based, allowing it to be ultra-sensitive. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity, ensuring exceptional performance.1 The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance.
This test is currently available for research use only (RUO).
Precise MRD test is an ultrasensitive, second-generation pan-tumor MRD test that is especially impactful for low tumor shedding cancers, such as breast, ovarian, and renal cancer. It has high sensitivity and specificity, among the best available.1
Our collaborations with leading organizations and investigators are crucial in advancing ultra-sensitive MRD testing for cancer treatment and monitoring.
1
2
In collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, the interim results demonstrated successful pan-cancer implementation of Myriad’s ultra-sensitive Precise MRD Test to detect and monitor ctDNA in patients:
“Our results showed that among samples that were ctDNA-positive at the one-month post-surgery timepoint, 60% had ctDNA levels in the ultra-sensitive range that may not have been reported as positive by first generation MRD tests. In addition, these patients had significantly worse disease-free survival compared to those that were ctDNA-negative, demonstrating the importance of ultra-sensitive ctDNA detection.”
- Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East (NCCHE), Japan, and principal investigator for the MONSTAR-SCREEN-3 study
Learn more
Myriad supports MRD investigator-initiated trials and other clinical study/trials.For outreach related to partnering on new or ongoing MRD studies/trials, please contact [email protected]
For investor relations outreach, please contact [email protected]
June 02, 2025 | Products | Pipeline
May 27, 2025 | Products | Pipeline
Apr 25, 2025 | Products
Jan 07, 2025 | Products | Corporate
Dec 09, 2024 | Products
Oct 08, 2024 | Products
Oct 01, 2024 | Products | Corporate
July 11, 2024
July 9, 2024
March 21, 2024
February 27, 2024
September 18, 2023
June 12, 2023
Reference: